EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling

Riccardo Moia iD, Lodovico Terzi di Bergamo, Donatella Talotta, Riccardo Bomben iD, Gabriela Forestieri, Valeria Spina, Alessio Bruscaggin, Chiara Cosentino, Mohammad Almasri, Riccardo Dondolin, Tamara Bittolo, Antonella Zucchetto und 26 weitere

British Journal of Haematology · 2023

DOI: 10.1111/bjh.19052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Riccardo Moia und 37 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy. Hauptthemen laut MEDLINE: Karyopherins, Receptors, Antigen, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Receptors, Cytoplasmic and Nuclear. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swiss National Science Foundation, Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Here we evaluated the epigenomic and transcriptomic profile of XPO1 mutant chronic lymphocytic leukaemia (CLL) and their clinical phenotype. By ATAC‐seq, chromatin regions that were more accessible in XPO1 mutated CLL were enriched of binding sites for transcription factors regulated by pathways emanating from the B‐cell receptor (BCR), including NF‐κB signalling, p38‐JNK and RAS‐RAF‐MEK‐ERK. XPO1 mutant CLL, consistent with the chromatin accessibility changes, were enriched with transcriptomic features associated with BCR and cytokine signalling. By combining epigenomic and transcriptomic data, MIR155HG , the host gene of miR‐155, and MYB , the transcription factor that positively regulates MIR155HG, were upregulated by RNA‐seq and their promoters were more accessible by ATAC‐seq. To evaluate the clinical impact of XPO1 mutations, we investigated a total of 957 early‐stage CLL subdivided into 3 independent cohorts ( N = 276, N = 286 and N = 395). Next‐generation sequencing analysis identified XPO1 mutations as a novel predictor of shorter time to first treatment (TTFT) in all cohorts. Notably, XPO1 mutations maintained their prognostic value independent of the immunoglobulin heavy chain variable status and early‐stage prognostic models. These data suggest that XPO1 mutations, conceivably through increased miR‐155 levels, may enhance BCR signalling leading to higher proliferation and shorter TTFT in early‐stage CLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KaryopherinsReceptors, Antigen, B-CellLeukemia, Lymphocytic, Chronic, B-CellReceptors, Cytoplasmic and NuclearMutationHumansExportin 1 ProteinSignal TransductionFemaleMaleMiddle AgedAgedMicroRNAs

Stichwörter der Autor:innen

BCRCLLXPO1

Substanzen

KaryopherinsExportin 1 ProteinReceptors, Antigen, B-CellReceptors, Cytoplasmic and NuclearMicroRNAs

Autor:innen und Institutionen

  • Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.
  • Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
  • Bioinformatics Core Unit, Swiss Institute of Bioinformatics, Bellinzona, Switzerland.
  • Department of Health Science and Technology, Swiss Federal Institute of Technology (ETH Zürich), Zurich, Switzerland.
  • Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  • Institute of Hematology, Center for Hemato-Oncology Research, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.

ORCID-Profile: Riccardo Moia, Riccardo Bomben, Ilaria Del Giudice, Francesca Romana Mauro, Rossana Maffei, Giovanni D'Arena, Paolo Sportoletti, Lydia Scarfò, Paolo Ghia, Robin Foà, Gianluca Gaidano

Förderung

  • Swiss National Science Foundation
  • Associazione Italiana per la Ricerca sul Cancro
  • Ministero della Salute
  • Ministero dell’Istruzione, dell’Università e della Ricerca
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Moia, R., Terzi di Bergamo, L., Talotta, D., Bomben, R., Forestieri, G., Spina, V., Bruscaggin, A., Cosentino, C., Almasri, M., Dondolin, R., Bittolo, T., Zucchetto, A., Baldoni, S., Del Giudice, I., Mauro, F. R., Maffei, R., Chiarenza, A., Tafuri, A., Laureana, R., …, & Gaidano, G. (2023). XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling. British Journal of Haematology. https://doi.org/10.1111/bjh.19052

Vancouver

Moia R, Terzi di Bergamo L, Talotta D, Bomben R, Forestieri G, Spina V, et al. XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling. British Journal of Haematology. 2023. doi:10.1111/bjh.19052

BibTeX
@article{Moia2023,
  author = {Moia, Riccardo and Terzi di Bergamo, Lodovico and Talotta, Donatella and Bomben, Riccardo and Forestieri, Gabriela and Spina, Valeria and Bruscaggin, Alessio and Cosentino, Chiara and Almasri, Mohammad and Dondolin, Riccardo and Bittolo, Tamara and Zucchetto, Antonella and Baldoni, Stefano and Del Giudice, Ilaria and Mauro, Francesca Romana and Maffei, Rossana and Chiarenza, Annalisa and Tafuri, Agostino and Laureana, Roberta and Del Principe, Maria Ilaria and Zaja, Francesco and D'Arena, Giovanni and Olivieri, Jacopo and Rasi, Silvia and Mahmoud, Abdurraouf and Al Essa, Wael and Awikeh, Bassel and Kogila, Sreekar and Bellia, Matteo and Mouhssine, Samir and Sportoletti, Paolo and Marasca, Roberto and Scarfò, Lydia and Ghia, Paolo and Gattei, Valter and Foà, Robin and Rossi, Davide and Gaidano, Gianluca},
  title = {XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.19052}
}
Kostenlos starten →